In patients with advanced refractory gastroesophageal cancer who had tried two other options, regorafenib improved overall survival when compared with placebo, offering a potential new treatment option.
Last year, the FDA approved almost a dozen novel cancer drugs and expanded indications for many more, while growing agency scrutiny led to numerous withdrawals.
The combination of zolbetuximab plus chemotherapy produced one of the longest overall survival outcomes ever seen for patients with advanced caludin18.2+ gastric or gastroesophageal junction cancer.